DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1956)

Chronic Myeloid Leukemia | Current Treatment | Detailed, Expanded Analysis (US)

Chronic Myeloid Leukemia | Current Treatment | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-ABL tyrosine kinase inhibitors. Treatment options for newly diagnosed chronic phase disease are dominated by TKIs, including first-to-market Gleevec (Novartis), Sprycel (Bristol-Myers Squibb), and Tasigna (Novartis); treatment options for patients who are resistant or intolerant to prior therapy (and in patients with accelerated and/or blast phase disease) include Bosulif (Pfizer), Iclusig (Ariad), and Synribo (Teva).

Questions Answered:

  • What percentage of drug-treated, newly diagnosed, chronic phase chronic myeloid leukemia patients are prescribed BCR-ABL tyrosine kinase inhibitors as first-line and second-line treatment by surveyed physicians?
  • What are the key drivers and obstacles determining current prescribing patterns in the chronic myeloid leukemia treatment armamentarium?
  • How the entry of generic Gleveec has affected the treatment preference of hematologists?
  • What are surveyed physicians’ perceptions of the intended duration of tyrosine kinase inhibitor treatment for​​​​​​ chronic myeloid leukemia versus their actual clinical practice? To what extent are their patients compliant?

Product Description:

Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Key Updates
      • December 2017
    • Introduction to Current Treatment for CML
      • Key Findings
      • Summary Figures
      • Introduction to Current Treatment and Medical Practice for CML
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • Less Than 30% of Newly Diagnosed Chronic Phase CML Patients Are Deemed at High Risk
      • Physician Treatment Practices for Newly Diagnosed Patients
        • Well-Established TKIs Dominate CML Treatment Armamentarium
        • Treatment Rates
        • Use of Nonpharmacological Approaches
        • Brand and Product Use for Newly Diagnosed Patients
        • Treatment Duration by Product
        • Physician Insight on Compliance and Persistency
      • Physician Treatment Practices for Recurrent Patients
        • The Choice of Agent Becomes More Fragmented in Later Lines of Chronic Phase CML Treatment
        • Treatment Rates
        • Brand and Product Use for Recurrent Patients
        • Treatment Duration by Product
        • Physician Insight on Compliance and Persistency
        • Disease Progression
      • Sequencing of Treatment
        • Only a Minority of Respondents Would Prescribe Bosulif After Resistance or Intolerance to First-Line TKI Therapy
      • Recent and Anticipated Changes in Treatment Practices
        • Nearly Half of Respondents Reported No Change in Use of Branded Gleevec After Entry of Generic Imatinib
    • Physician Insight on Medical Practice
      • Key Findings
      • Factors Influencing Treatment Practice
        • Major Drivers of Brand Use/Treatment
        • Major Obstacles to Brand Use/Treatment
        • Insight on Treatment Failure/Brand Issues
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: December 2017
  • Author(s): Swati Tyagi, M.Sc, MBA
  • Swati Tyagi, is a Senior Business Insight Analyst in the oncology team at the Decision Resources Group. She comes with 8 years of work experience from the life sciences market research industry. She has in-depth expertise in competitive intelligence, secondary and primary research, and strategic projects across multiple oncology indications. Prior to joining the company, she was a delivery manager in a market research organization, where she was handling a major client engagement account and a dedicated team of senior and business analysts working for the specialty medicine brands of the client. She holds an in biotechnology and MBA from Amity University, India.

Purchase Report

Recent reports:
You may also be interested in: